SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation

Lupus

Volumn 20, Issue 1, 2011, Pages 67-70

  Touma, Z ^a   Urowitz, M B ^a   Ibanez D ^a   Gladman, D D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

disease activity; lupus; SLEDAI 2K

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ACTIVITY; EVALUATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 78751559483     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310385163     Document Type: Article

References (14)

1. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
2. Gladman DD, Ibanez D., Urowitz MB Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002 ; 29: 288-291.
3. Isenberg DA, Rahman A., Allen E., et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005 ; 44: 902-906.
4. Bencivelli W., Vitali C., Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992 ; 10: 549-554.
5. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001 ; 10: 405-409.
6. Touma Z., Urowitz MB, Gladman DD SLEDAI-2K for a 30-day window. Lupus 19: 49-51.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277.
8. Nikpour M., Urowitz MB, Ibanez D., Gladman DD Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009 ; 61: 1152-1158.
9. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000 ; 27: 373-376.
10. Hay EM, Bacon PA, Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993 ; 86: 447-458.
11. Mosca M., Bencivelli W., Vitali C., Carrai P., Neri R., Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000 ; 9: 445-450.
12. Petri M., Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005 ; 353: 2550-2558.
13. Ward MM, Marx AS, Barry NN Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000 ; 27: 664-670.
14. Strand V., Gladman D., Isenberg D., Petri M., Smolen J., Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999 ; 26: 490-497.